March 3, 2020 / 1:08 PM / a month ago

IN BRIEF: With trial looming, Novartis settles patent cases over generic Gilenya

Novartis AG on Saturday told a judge it had settled patent infringement cases against two generic drug companies vying to launch versions of its blockbuster multiple sclerosis drug Gilenya, averting a trial.

In two separate notices filed in Delaware federal court, Novartis and its lawyers at Gibson Dunn & Crutcher said they had settled claims that generic versions of Gilenya proposed by Hetero Drugs Ltd and Zydus Pharmaceuticals Inc would infringe one of the Swiss drugmaker’s patents.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below